Asthma is a heterogeneous disease characterized by chronic airway inflammation, typically sustained by T H 2 cells and eosinophils. 1 Several types of asthma feature neutrophilia such as intrinsic asthma 2 ; asthma in the elderly, 3 smokers, 4 or obese females 5 ; and a category of severe asthma (SA). 6 Neutrophilic SA can be distinguished in 2 subtypes featured by absence or presence of eosinophils. 6 T H 17 cells seem to play a relevant role in SA related to bronchial neutrophils. 7, 8 IL-17A/F increased expression has been demonstrated in bronchial mucosa of moderate-to-severe asthma. [8] [9] [10] Moreover, IL-8 is prominently expressed in airways secretions of acute SAs, 11 and neutrophil airway infiltration is commonly reported in SA, 12 suggesting a key role for T H 17 cells. Although the main function of T H 17 cells is supposed to be induction of protection against potentially harmful fungi and extracellular bacteria, many experiments revealed that T H 17 cells also drive tissue inflammation in patients with several autoimmune diseases and allergy. 13, 14 These cells entail distinct phenotypes of CD4/CD8 1 cells, characterized by IL-17A, IL-17F, IL-21, and IL-22 production. 13, 14 T H 17 cell differentiation is mainly regulated by IL-23, which is structurally related to IL-12, 13, 14 and whose serum levels are increased and negatively correlated with FEV 1 in asthmatic children. 15 IL-17A/ F induce the release of chemokines, such as CXCL1 (GROa), CXCL8 (IL-8), and GM-CSF from airway epithelial cells and smooth muscle cells: these substances are involved in neutrophilic infiltration. 16, 17 IL-17A/F act on a multiplicity of cells, which respond with upregulation of proinflammatory cytokines, chemokines, and/or metalloproteases. 18, 19 A study demonstrated that IL-17 is able to increase IL-6 and IL-11 synthesis in bronchial fibroblasts derived from asthmatic bronchial biopsies playing an indirect role in asthma remodelling. 20 Asthma phenotypes, and more specifically asthma endotypes, are considered essential in clinical practice because of their potential help to predict treatment response. 21 Recently, the frequent exacerbator (FE) phenotype has been described, which is significantly more prone to exacerbations. 22 It is known that several comorbidities, including upper airways disorders, 23 and overall exacerbations 24 may be risk factors for asthma severity.
Different studies showed a close relationship between upper and lower airways in asthma, indeed rhinitis is considered the main risk factor for asthma onset/worsening. 25 Moreover, nasal eosinophils correlate both with bronchial and nasal airflow limitations. 25 In addition, T H 17-driven inflammation may affect both upper and lower airways. 8, 26, 27 This study, which is an extension of a previous study, 8 aimed to evaluate the expression of IL-17-related cytokines in nasal/bronchial biopsies obtained from control subjects and atopic/nonatopic mild asthmatics (MAs) to SAs focusing on exacerbation rate. Finally, IL-17F expression was also examined in fatal asthma.
METHODS

Asthmatic and control subjects
In this observational and cross-sectional study, bronchial biopsies from 78 subjects were analyzed: 33 SAs, 31 MAs, and 14 controls; clinical/demographic characteristics are shown in Table I . Asthma diagnosis/severity were defined according to Global Initiative for Asthma (GINA) and European Respiratory Society/American Thoracic Society guidelines. 1, 28 Rhinitis/chronic sinusitis were defined according to guidelines. 29, 30 Allergy was assessed by skin prick tests/serum-specific IgE, 29 and all subjects performed lung function test and fractional exhaled NO as described in Online Repository at www.jacionline.org. Controls had no respiratory disease history and no airflow limitation. All subjects were in stable condition (see also Online Repository). FEs are defined subjects who have > _2 asthma exacerbations/year that require use of systemic corticosteroids (or an increase from a stable maintenance dose) for at least 3 days or a hospitalization/emergency department visit because of asthma requiring systemic corticosteroids. 22 
Statistical analysis
Data were analyzed using Graph Pad Prism software (version 5.0; GraphPad Software Inc, San Diego, Calif). Clinical/functional variables are expressed as means 6 SDs, morphological parameters as medians (interquartile ranges). A normal and nonnormal distribution were assumed, respectively, for clinical/functional data and morphological parameters applying, respectively, ANOVA or the nonparametric Kruskal-Wallis test for multiple comparisons and the Student t test or the Mann-Whitney U test for comparisons between groups. Spearman rank method was used for correlations. A receiver operating characteristic (ROC) curve was used to assess the accuracy of bronchial/nasal IL-17F in discriminating between asthmatics and controls, MA and SA and between FE and non-FE (see also Online Repository). The area under the curve (AUC) with the 95% confidence intervals was calculated for each ROC curve, and the best cutoff point was chosen based on the Youden index. P values of less than .05 were considered statistically significant, and ROC curves were constructed using R 3.3.1 software environment (R Foundation, Vienna, Austria). 33 
RESULTS
Inflammatory cells in bronchial/nasal mucosa
The numbers of inflammatory cells (neutrophils, eosinophils, and CD4
1 and CD8 IL-17A/F were significantly increased in asthmatics compared with controls both in bronchial (P < .01 and P < .01, respectively) and nasal (P < .05 and P < .001, respectively) mucosa, as well as bronchial IL-21 (P < .01), IL-22 (P < .001), IL-23 (P < .01), and nasal IL-21 (P < .01), IL-22 (P < .01), and IL-23 (P < .0001).
IL-17A/F and IL-21 were more expressed in the bronchial mucosa of SAs compared with both MAs and controls (P < _ .01) (Fig 2, A) . Bronchial IL-17F and IL-21 were higher in MAs compared with controls (P < .05) (Fig 2, A) . Bronchial IL-22 and bronchial IL-23 were increased both in SAs (P < .05) and MAs (P < .01) compared with controls (Fig 2, A) . Nasal IL-17F and IL-21 were significantly higher in SAs compared with MAs and controls and IL-17F also in MAs compared with controls (P < .01) (Fig 2, B) . Nasal IL-17A expression was significantly increased only in SAs compared with controls (P < .05) (Fig 2, B) .
Finally, nasal IL-22 and nasal IL-23 were higher in SAs (P < .001) and MAs (P < .05) compared with controls (Fig 2, B) . Concerning the bronchial and nasal epithelium, IL-17F expression was higher in SAs compared with both MAs and controls both in bronchial and nasal mucosa (see Table E1 in this article's Online Repository at www.jacionline.org).
Correlations between IL-17-related cytokines/ inflammatory cells and clinical parameters
In all asthmatics, both bronchial and nasal IL-17F expression was negatively related to FEV 1 (r s 5 20.46, P < .0005 and r s 5 20.61, P < .0005, respectively) (Fig 3, A and E) . Concurrently, both bronchial and nasal IL-17F expression was positively related to exacerbation rate (r s 5 0.41, P < .005 and r s 5 0.47, P < .0005, respectively) (Fig 3, B and F) . In all asthmatics, a negative correlation between FEV 1 and exacerbations number was also observed (r s 5 20.47, P < .0005) (Fig 3, J) (Fig 3, I ) and exacerbation rate (r s 5 0.47, P <.0005) (Fig 3, K) . Correlations between forced vital capacity and IL-17-related cytokines are shown in this article's Online Repository (see Fig E5 at www.jacionline.org).
Correlations between inflammatory cells and bronchial/nasal IL-17-related cytokines
In all asthmatics, bronchial IL-17F 1 cells correlated with bronchial neutrophils (r s 5 0.54, P < .0005) (Fig 3, C) , bronchial IL-17A 1 (r s 5 0.67, P < .0005) (Fig 3, D) , bronchial IL-21 1 (r s 5 0.30, P < .05) (see Fig E6, A in this article's Online Repository at www.jacionline.org), bronchial IL-22 1 (r s 5 0.29, P < .05) (see Fig E6, Table I . Concerning inflammatory cells expression in the bronchial/nasal mucosa, bronchial neutrophils, eosinophils, and CD4
1 and CD8 1 cells were significantly increased in FEs compared with non-FEs (P < .05) (Fig 4) . Regarding IL-17-related cytokines, both bronchial (P < .001) and nasal (P < .001) IL-17F showed significantly higher expressions in FEs compared with non-FEs, as well as bronchial IL-17A, nasal IL-21, and nasal IL-22 (P < .05) (Fig 4) .
ROC curve analysis
ROC curve analysis of bronchial neutrophils and bronchial eosinophils showed a significant AUC of 0.81 and 0.94, respectively, for discriminating asthmatics from healthy controls (Fig 5, A) . The best cutoff value for bronchial neutrophils was 47.17 cells/mm 2 , whereas for bronchial eosinophils, it was 
cells/mm
2 . For the discrimination of MA from SA, significant AUC values of 0.75 for neutrophils were estimated and the best cutoff value for bronchial neutrophils was 50.31 cells/mm 2 (Fig 5, B) . Finally, ROC curve analysis among all asthmatics for discriminating the FE phenotype (Fig 5, C) showed significant AUC values of 0.84 and 0.77 for neutrophils and eosinophils, respectively. The best cutoff values for neutrophils and eosinophils were 78.62 cells/mm 2 and 37.74 cells/mm 2 , respectively. ROC curve analysis of bronchial/nasal IL-17F showed a significant AUC of 0.84 and 0.85, respectively, for discriminating asthmatics from healthy controls (Fig 5, D) . A best cutoff value of 10.29 cells/mm 2 for bronchial IL-17F was estimated, whereas for nasal IL-17F, it was 11.32 cells/mm 2 .
To differentiate between MA and SA, a significant AUC of 0.73 and 0.83 was estimated for bronchial and nasal IL-17F, respectively (Fig 5, E) . The best cutoff value for bronchial IL-17F was 23.58 cells/mm 2 , whereas for nasal IL-17F, it was 18.87 cells/mm 2 . Finally ROC curve analysis among all asthmatics for discriminating the FE phenotype (Fig 5, F) showed for bronchial IL-17F a significant AUC of 0.79 and a related best cutoff value of 23.58 cells/mm 2 and for nasal IL-17F, a significant AUC of 0.78 and a related best cutoff value of 26.41 cells/mm 2 . The percentages of sensitivity, specificity, positive predictive value and negative predictive value for all variables in all subgroups are reported in Table E2 in the Online Repository.
IL-17F in bronchial/nasal lysates
Bronchial IL-17F lysates concentrations in SAs (n 5 10; 64 6 14 pg/mL) were significantly higher compared with MAs (n 5 10; 43 6 15 pg/mL; P < .01) and controls (n 5 8; 29 6 5 pg/mL; P < .001) (Fig 6) . In addition, nasal IL-17F lysates concentrations in SAs (n 5 10; 72 6 22 pg/mL) were significantly higher compared with MAs (n 5 10; 47 6 12 pg/mL; P <.01) and controls (n 5 8; 35 6 9 pg/mL; P < .001) (Fig 6) . Bronchial and nasal IL-17F lysates concentrations in FEs (n 5 10 and n 5 9, respectively) were significantly increased compared with non-FEs (n 5 10 and n 5 11, respectively; P < _ .001).
Double staining/confocal microscopy for CD4
1 and CD8
1 cells with IL-17F in the bronchial/nasal mucosa of asthmatics
In bronchial/nasal mucosa of asthmatics merging the green (IL-17F) and red (CD4 1 or CD8 1 cells) pixels revealed that IL-17F positivity coexpressed CD4 1 or CD8 1 cells (yellow pixels) (Fig 7) .
Colocalization by quantitative analysis in SAs (n 5 6) showed that among all IL-17F 1 cells 26.5 6 5% and 22. ROC curves for optimal cutoff points at which bronchial (Br) neutrophils and bronchial eosinophils discriminate asthmatic patients from healthy controls (A), SAs from MAs (B) and asthma FE from asthma non-FEs (C). ROC curves for optimal cutoff points at which bronchial and nasal (Ns) IL-17F discriminate asthmatic patients from healthy controls (D), SAs from MAs (E), and asthma FE from asthma non-FEs (F).
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1 lymphocytes in the bronchial and nasal mucosa, respectively. The differences between SAs and MAs and between FEs and non-FEs (n 5 5) were not statistically significant both in bronchial and nasal mucosa.
In bronchial mucosa of FEs (n 5 3) the colocalization of IL-17F 1 /neutrophil elastase 1 cells was 7.3 6 4%, but it was almost absent for IL-17F 
IL-17F expression in fatal asthma
IL-17F and neutrophils expression was evaluated in a small group of subjects (n 5 10) who died because of a fatal asthma attack and of controls (n 5 10). IL-17F was significantly higher in fatal asthma patients than in controls (P < .05) (Fig 8) , but no significant difference was observed for neutrophils between the 2 groups (P 5 .68) (see Fig E9 in this article' s Online Repository at www.jacionline.org).
DISCUSSION
This study showed higher expression of IL-17-related cytokines, especially of IL-17F, in the nasal/bronchial mucosa of atopic/nonatopic SAs compared with MAs and controls. IL-17F was significantly related to bronchial neutrophilia, FEV 1 , and exacerbation rate in all asthmatics. In particular, phenotyping the population of asthmatics in FEs and non-FEs, both nasal and bronchial IL-17F expression in conjunction with bronchial neutrophils (and to a lesser extent with eosinophils and CD4 1 and CD8
1 cells) was considerably increased in asthmatic FEs. Furthermore, IL-17F protein increased in bronchial/nasal lysates of SAs and FEs in line with immunohistochemistry results. ROC curve analysis allowed us to identify an optimal predictive cutoff value of bronchial neutrophils and nasal/bronchial IL-17F for discriminating asthmatics, SAs, and FEs. Finally, bronchial IL-17F expression was higher in fatal asthma patients than in controls.
Bronchial mucosa in SAs was characterized by a more intense neutrophilic infiltration compared with MAs and controls, suggesting that SA is typified by a distinct neutrophilic phenotype with increased expression of T H 17-related cytokines (IL-17F, IL-17A, and IL-21) at bronchial level. Among asthmatics, neutrophils and nasal/bronchial IL-17F were significantly increased in FEs compared to non-FEs as well as bronchial IL-17F/A correlated with bronchial neutrophils in all asthmatics, strengthening the link between T H 17 cytokines and neutrophilia in relation to disease severity and exacerbation rate. This pivotal role of nasal/bronchial IL-17F was confirmed by ROC curve analysis. The tendency of higher IL-17F expression in bronchial mucosa of fatal asthma patients versus deceased controls unveils the involvement of this biomolecular pathway in the risk of death due to asthma.
Initially, Sun et al 34 showed IL-17A protein increase in induced sputum from SAs compared with from controls, which was accompanied by a rise in sputum neutrophils. The investigators Each column represents mean 6 SD. *P < _.05, **P < _.001, and *** P < _.0001. also examined IL-17A protein in all disease stages and found that IL-17A increase in sputum clearly paralleled disease severity in conjunction with the concentrations of both the neutrophilrecruiting chemokine IL-8 and the activity marker myeloperoxidase, thus illustrating IL-17A association with neutrophil mobilization in asthma.
34 IL-17A was described in bronchial tissue from asthmatics with a more marked expression in MA to SA. 35 This increase was complement to the corresponding TGF-b and type I collagen increase, showing the involvement of IL-17A-producing cells in remodelling. 35 Al-Ramli et al 9 demonstrated that the magnitude of the increase in bronchial IL-17A matches with disease severity and that this increase is robust in SAs, supporting the idea that IL-17A is involved in SA pathogenesis. 36 Similarly, the relevant role of IL-17F in asthma was demonstrated, 37 evidencing that also this cytokine stimulates the production and release of neutrophil-mobilizing cytokines (eg, GM-CSF and IL-8) in human bronchial epithelial cells 37 and bronchial fibroblasts. 14, 38 Some studies referred an increase of IL-17F expression in bronchial lamina propria related to disease severity 9,10 and, interestingly, Al-Ramli et al 9 found IL-17F protein in the epithelial layer and even within epithelial cells in the very same patients that expressed IL-17A in asthmatics' submucosa, suggesting that both cytokines may be expressed simultaneously. There is now a growing evidence that, just like neutrophils per se, IL-17A/F are critically involved in mammalian host defense against bacteria, fungi and, possibly, viruses; thus, these 2 cytokines as well as the IL-17RA/RC receptor complex they share emerge as promising therapeutic targets. 7 Concerning IL-21, we observed a significant increase in SAs compared with MAs and controls either in nasal or bronchial mucosa. IL-21 acts in an autocrine manner to promote IL-17A production and further inhibits IFN-g production from T H 1 cells. 39, 40 The current study also showed an increased expression of IL-22 and IL-23 in the nasal/bronchial mucosa of both MAs and SAs compared with controls and, additionally, both IL-21 1 cells in the bronchial and nasal mucosa of asthma FEs. IL-17F positivity is showed in green (AF488) and positivity for CD4 or CD8 is showed in red (AF568), colocalization is showed in the merge panel as yellow pixels. In the cytofluorogram, colocalization is represented the as blue pixels. Original magnification 10003.
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and IL-22 were higher in the nasal mucosa of FEs than non-FEs, indicating a role for IL-21 and IL-22 in modulating IL-17 cascade in asthma, particularly in the nose of subjects prone to exacerbations. IL-22 is expressed by T H 17 cells and promotes innate immunity against infection, which connect the immune response to tissue inflammation. 41 Both IL-17 and IL-22 play roles in immune defense to extracellular bacteria: IL-17 contributing to antibacterial immunity and IL-22 promoting epithelial proliferation and repair following injury. 42 Furthermore, IL-23 is the most important differentiating cytokine, with proinflammatory properties, which drives the immune response toward T H 17 cells. In asthma, IL-23 promotes T H 17 cells' proliferation to maintain IL-17A/F production and neutrophils recruitment, indicating that the IL-23-T H 17 axis might become a novel therapeutic target especially for the severe corticosteroiddependent asthma. 43 A recent study 44 suggested that IL-17/ IL-23 cytokines hamper both anti-inflammatory and immunosuppressant actions of glucocorticoids in peripheral lymphocytes via increased glucocorticoid receptor-b-glucocorticoid receptor-a ratios.
The nasal mucosa of SAs showed a significantly more abundant infiltrate of CD4 1 and CD8 1 cells compared with those of MAs and controls, together with an increased nasal expression of IL-17F and IL-21, whereas nasal IL-17A, IL-22, and IL-23 were enhanced in all asthmatics compared with controls. A significant positive correlation between the number of IL-17A 1 cells in sinonasal tissues and the sinusitis radiologic severity was observed in chronic rhinosinusitis with nasal polyps by Makihara et al, 27 who also found a significant negative correlation between the number of IL-17A 1 cells and FEV 1 -forced vital capacity ratio. Furthermore, it has been shown that T H 17 cells may promote both eosinophilic and neutrophilic inflammation in allergic rhinitis and chronic rhinosinusitis. 45 Thus, SA is characterized by a more intense T H 17-polarized nasal inflammation than MA confirming the close pathogenic association between nose and bronchi independently of atopic status. Nasal inflammation appears to play a relevant role in worsening lower airways function as previously demonstrated. 25 The role of T H 17 cytokines in an asthmatic's nose is further emphasized by the significant correlation between nasal IL-17F
1 and bronchial IL-17F 1 cells, FEV 1 (negative) or exacerbations number (positive), suggesting a similar pattern and degree of inflammation in upper and lower airways in asthma related to severity. This study strengthens the concept of united airways disease, 46 as nasal inflammation severity is constantly associated with asthma severity: the nose should be ever assessed in asthmatics and envisaged as the window of bronchi. 47 In all asthmatics a positive correlation between IL-17F and neutrophils in the bronchial mucosa and a negative correlation between both nasal and bronchial IL-17F and FEV 1 or forced vital capacity were observed, confirming consistently with our previous study 8 the direct role for IL-17F in nasal/bronchial neutrophils recruitment and in lung function decline in asthma. 9 A positive correlation between nasal and bronchial IL-17F 1 cells and exacerbations number was also evidenced, indicating that IL-17F can be associated to exacerbation frequency, which is a strong risk factor for pulmonary function decline 24, 48 and nearfatal events in SAs. 23 The current study also demonstrated higher numbers of bronchial CD4
1 and CD8 1 cells in FEs, both in relationship with bronchial IL-17F in all asthmatics and the colocalization of IL-17F in CD8 1 (25%) and CD4 1 lymphocytes (25%) in the bronchial/nasal mucosa of asthmatics, indicating an immune modulator role depending on IL-17 cascade for both T-cell subsets. Thereupon, Annunziato et al 14 recently reported that the innate and adaptive immune response converge into 3 major kinds of cell-mediated effector immunity categorized as type 1, type 2, and type 3 that respond to distinct species of microbes. In particular, type 3 immunity is mediated by retinoic acid-related orphan receptor-gt 1 innate lymphoid cell 3s, T c 17 cells, and T H 17 cells producing IL-17, IL-22, or both, which promote neutrophils recruitment in tissues and induce antimicrobial peptide production by epithelial cells, thus protecting against extracellular bacteria and fungi. 14 The use of high inhaled corticosteroid doses and oral corticosteroids maintenance therapy in SAs and FEs compared with low inhaled corticosteroid dose in MAs and non-FEs could be a limitation of this study. Previous reports showed that neutrophil survival is increased by corticosteroids, 49 suggesting that daily inhaled corticosteroid high doses could influence neutrophil counts but, on the other hand, oral corticosteroids treatment reduced sputum neutrophils in SAs. 50 In addition, it is fundamental to point out that IL-17 provokes steroid insensitivity in PBMCs by glucocorticoid receptor-beta upregulation 44 and steroid-resistant neutrophil activity, suggesting that IL-17 directly induces insensitivity of neutrophils to corticosteroids. 51 In conclusion, the current study confirms previous preliminary data 8 on nasal/bronchial IL-17F, extending to a larger population of both atopic and nonatopic asthmatics, in conjunction with a role for IL-17A and IL-21 in neutrophilic SA. Moreover, this study highlights the importance of nasal and bronchial IL-17F expression as a potential biomarker to identify the FE endotype among asthmatics. These factors might allow us to obtain an early prognosis that is clinically relevant to predicting treatment response to specific therapeutic options against IL-17F in asthma and to improving the clinical management of the respiratory disability in FE as well as considering the risk of asthma death.
Key messages
d Increased expression of IL-17-related cytokines in nasal and bronchial tissues of severe asthmatics is related to neutrophilic inflammation, airway obstruction, and exacerbation rate. 
